Subchronic administration of phenobarbital alters the mutation spectrum of lacI in the livers of Big Blue transgenic mice.
Phenobarbital (PHE) is a liver carcinogen in B6C3F1 mice and a weak mutagen that does not appear to form DNA adducts. To investigate PHE mutagenicity in vivo, B6C3F1 Big Blue(R) male transgenic mice harboring the lambdaLIZ shuttle vector containing the lacI target gene were fed PHE at 2500 ppm for 180 days. A modest increase in the mutant frequency (MF) from 5.02+/-2.4x10(-5) in the control group to 6.88+/-0.754x10(-5) in the PHE-treated group, which was marginally different (p<0.05), was obtained. To better assess the relevance of this increase in MF, a random collection of mutants from each PHE-exposed mouse was sequenced. After correcting for clonal expansion, which is the most conservative approach, the MF in the PHE-treated mice decreased to 6.39+/-1.02x10(-5), an insignificant difference (p=0.10) from that in control group. Despite this modest increase in MF, the mutation spectrum obtained from the PHE-exposed group was significantly different (pA:T transitions remained the same in the two spectra. It is postulated that the increase in transversions at G:C base pairs found in the PHE-derived spectrum is likely due to oxidative damage as a result of induction of CYP2B isozymes by the chronic administration of PHE. Results from this study demonstrate that PHE alters the spectrum of mutations, rather than inducing a significant global increase in the MF. The PHE-derived spectrum of lacI mutants from the liver of Big Blue(R) B6C3F1 male mice was remarkably similar (p=0.8) to that generated by oxazepam (OX), a compound which also induces CYP2B isozymes following chronic administration of the drug.
Shane
B S
BS
Institute for Environmental Studies, 42 Atkinson Hall, Louisiana State University, Baton Rouge, LA 70803, USA. bshane@lsu.edu
Smith-Dunn
D L
DL
deBoer
J G
JG
Glickman
B W
BW
Cunningham
M L
ML
D000818:Animals; D001426:Bacterial Proteins / Q000187:drug effects* / Q000235:genetics; D004334:Drug Administration Schedule; D029968:Escherichia coli Proteins; D006993:Hypnotics and Sedatives / Q000008:administration & dosage / Q000494:pharmacology*; D056968:Lac Repressors; D008099:Liver / Q000187:drug effects*; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D008934:Mitogens / Q000008:administration & dosage / Q000494:pharmacology; D009152:Mutagenicity Tests / Q000379:methods; D009154:Mutation; D010634:Phenobarbital / Q000008:administration & dosage / Q000494:pharmacology*; D012097:Repressor Proteins / Q000187:drug effects* / Q000235:genetics
D001426:Bacterial Proteins; D029968:Escherichia coli Proteins; D006993:Hypnotics and Sedatives; D056968:Lac Repressors; D008934:Mitogens; D012097:Repressor Proteins; D010634:Phenobarbital